Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
University Hospital Ulm · University of Pennsylvania · +15 more institutions
Abstract
ABSTRACT: The European LeukemiaNet (ELN) acute myeloid leukemia (AML) genetic risk classification systems are based on response to intensive chemotherapy; their ability to discriminate outcomes in older patients treated with venetoclax-azacitidine may be suboptimal. This pooled analysis of the phase 3 VIALE-A trial (NCT02993523) and phase 1b study (NCT02203773) examined prognostic stratification according to the 2017 and 2022 ELN risk classifications and derived new molecular signatures differentiating venetoclax-azacitidine-treated patients based on overall survival (OS). Overall, 279 patients treated with venetoclax-azacitidine and 113 patients treated with placebo-azacitidine were analyzed. The ELN 2017 or…
Citation impact
- FWCI
- 51.70
- Percentile
- 100%
- References
- 25
Authors
18- HDHartmut DöhnerCorresponding
University Hospital Ulm
- KWKeith W. Pratz
University of Pennsylvania
- CDCourtney D. DiNardo
The University of Texas MD Anderson Cancer Center
- AHAndrew H. Wei
The Royal Melbourne Hospital, The University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Peter MacCallum Cancer Centre
- BABrian A. Jonas
University of California, Davis
Topics & keywords
- Venetoclax
- Azacitidine
- Medicine
- Internal medicine
- Oncology
- Myeloid leukemia
- Placebo
- Leukemia
- Reduced inequalities